Search results for "Bypassing agents"

showing 3 items of 3 documents

Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBi…

2020

Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may still occur while on emicizumab, requiring treatment with bypassing or other haemostatic agents. Thrombotic complications have been reported with the associated use of activated prothrombin complex concentrates. In addition, when surgery/invasive procedures are needed while on emicizumab, their management requires multidisciplinary competences and direct supervision by experts in the use of this agen…

Factor VIIIFVIII inhibitorSettore BIO/12Antibodies Bispecific Antibodies Monoclonal Humanized Factor VIII Hemophilia A Hemorrhage Hemostatics Humans Italy Quality of LifeFVIII inhibitorsHemorrhageAntibodies Monoclonal HumanizedHemophilia AAntibodiesHemostaticsbypassing agents; emergency; emicizumab; FVIII inhibitors; haemophilia AItalyhemic and lymphatic diseasesMonoclonalEmergencyHaemophilia AAntibodies BispecificQuality of LifeHumansBispecificBypassing agentsEmicizumabHumanizedBypassing agentHaemostasis
researchProduct

A perioperative uncontrollable bleeding in an elderly patient with acquired hemophilia A: a case report

2013

Key Clinical Message Acquired hemophilia A should be taken into account in the differential diagnosis of perioperative bleeding in patients without any apparent reason for activated partial thromboplastin time prolongation.

bleeding disordersPediatricsmedicine.medical_specialtymedicine.diagnostic_testAcquired hemophilia A; bleeding disorders; bypassing agentsbusiness.industryAcquired hemophilia ASettore MED/41 - AnestesiologiaAcquired hemophilia A bleeding disorders bypassing agents.Case ReportsGeneral MedicinePerioperativehemic and lymphatic diseasesAcquired hemophiliaMedicineIn patientDifferential diagnosisbusinessElderly patientbypassing agentsPartial thromboplastin time
researchProduct

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

2019

Background: Bypassing agents are the first line therapy in patients with acquired haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be effective as initial treatment, but 20% of patients (pts) had relapses. aPCC as short-term prophylaxis to reduce subsequent bleeds is still not clear. Aim: To evaluate whether a short-term prophylaxis with low dose of aPCC can reduce bleeding relapses after initial AHA treatment, maintaining safety. Methods: The FAIR Registry is a retrospective-prospective study started on December 2012, that collected data on all pts with AHA treated with aPCC in 12 Italian Haemophilia Centers. All statistical analyses were carried out in the 5…

Malemedicine.medical_specialtyAcquired haemophilia; Bleeding relapses; Bypassing agents; Prophylaxis; Aged; Female; Hemophilia A; Hemorrhage; Humans; Male; Prospective Studies; Recombinant Proteins; Recurrence; Retrospective StudiesHemorrhage030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineFirst line therapyRecurrenceInternal medicineAcquired haemophiliamedicineHumansInitial treatmentIn patientProspective StudiesProphylaxiActivated prothrombin complex concentrateBypassing agentAgedRetrospective StudiesHematologyProphylaxisbusiness.industryLow doseBleeding relapseHematologymedicine.diseaseRecombinant Proteins030220 oncology & carcinogenesisFemaleBleeding relapsesBypassing agentsbusinessAcquired haemophiliaThrombosis Research
researchProduct